A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Summary

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Timeline

Start

2025-12-10

Primary completion

2027-03-18

Completion

2027-05-08

Drugs

Indications